Last Updated: June 26, 2026

Claims for Patent: 7,968,317

✉ Email this page to a colleague

Summary for Patent: 7,968,317

Title:	Detection of 5T4 RNA in plasma and serum
Abstract:	This invention provides methods for detecting the presence of malignant or premalignant cells, or trophoblastic cells in a human wherein the malignant, premalignant or trophoblastic cells express 5T4. The methods of the invention detect 5T4 RNA in blood, blood plasma, serum, and other bodily fluids. The inventive methods are useful for detection, diagnosis, monitoring, treatment, or evaluation of neoplastic disease, and for the detection and evaluation of placental tissue in pregnant women.
Inventor(s):	Kopreski; Michael S. (Long Valley, NJ), Gocke; Christopher D. (Elliott City, MD)
Assignee:	OncoMedx, Inc. (Long Valley, NJ)
Application Number:	11/415,968
Patent Claims:	1. A method of detecting 5T4 RNA or beta-human chorionic gonadotropin (beta-HCG) RNA in blood plasma or serum from a woman with a gestational trophoblastic neoplasia that is said 5T4 RNA or beta-HCG RNA-expressing neoplasia comprising the steps of: a) extracting extracellular RNA from blood plasma or serum from a woman having a gestational trophoblastic neoplasia that is 5T4 RNA or beta-HCG RNA-expressing neoplasia, wherein a portion of the extracellular RNA comprises said 5T4 RNA or beta-HCG RNA; b) amplifying a portion of the extracellular RNA or cDNA prepared therefrom and producing an amplified product, wherein the amplification is performed in either a qualitative or quantitative fashion using oligonucleotide primers specific for said 5T4 RNA or cDNA produced therefrom, or for said beta-HCG RNA or cDNA produced therefrom; and c) detecting said 5T4 RNA in the blood plasma or serum from said woman by detecting the amplified product when the amplification is performed using said oligonucleotide primers specific for said 5T4 RNA or cDNA produced therefrom, or detecting said beta-HCG RNA in the blood plasma or serum from said woman by detecting the amplified product when the amplification is performed using said oligonucleotide primers specific for said beta-HCG RNA or cDNA produced therefrom.

Details for Patent 7,968,317

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	7,968,317	2026-05-02
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	7,968,317	2026-05-02
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	7,968,317	2026-05-02
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	7,968,317	2026-05-02
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	7,968,317	2026-05-02
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.